Los Angeles, California – “Venom: The Last Dance” has taken the top spot at the box office, but the latest installment in the Marvel antihero series has fallen short of expectations, disappointing fans and industry insiders alike.

Despite the international success of “Venom 3,” which has grossed $175 million globally, the North American opening weekend numbers are far below projections. The film, led by Tom Hardy reprising his role as investigative journalist Eddie Brock and the alien symbiote Venom, debuted to a lackluster $51 million domestically, well below the $65 million predicted by rival studios.

Critics have not been kind to the latest installment, giving it a 37% rating on Rotten Tomatoes, while audience members graded it a “B-” on CinemaScore, the lowest of the trilogy. Analysts point to a lack of excitement and higher stakes in “The Last Dance” as potential reasons for the lukewarm reception.

Expensive productions like “Venom: The Last Dance,” which cost $120 million to produce, need strong box office returns to justify their investment. With the original “Venom” earning $856 million worldwide and its sequel, “Venom: Let There Be Carnage,” surpassing $500 million, the pressure is on for the third installment to perform well. However, with a poor critical reception and tepid audience reactions, the future of the franchise remains uncertain.

The box office landscape remains challenging, with overall returns behind previous years due to a lack of major releases. With upcoming titles like “Here” and “Red One” set to hit theaters, industry experts are hopeful for a boost in ticket sales. However, with the absence of blockbuster releases until later in the month, the state of cinema-going remains in flux.

In a surprising turn, the thriller “Conclave” exceeded expectations, opening at No. 3 with $6.5 million in ticket sales. The tense Vatican drama has garnered solid reviews and aims to make a mark in the upcoming awards season. With audiences responding positively to the film, there is hope for its continued success in the coming weeks.

As the industry grapples with shifting audience preferences and a challenging box office landscape, the fate of blockbuster films like “Venom: The Last Dance” hangs in the balance. With competition from other releases and changing consumer behaviors, the road ahead for Hollywood remains uncertain.